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THE malfunctioning of proteins often has an impact on cellular ac-tivity in that disturbances may occur in cellular functioning andmetabolism. As a consequence, impairment of physiological func-
tions may take place, leading to diseases. Defects in one or more proteins,
resulting, for example, from mutations in their genes, can trigger prolifer-
ative signaling, cause resistance to cell death, or induce invasiveness, all
of which are processes that may trigger the development of cancer. Ba-
sic cancer therapy often relies on treatment with cell-killing or cell-growth
inhibiting chemical substances, also known as chemotherapy. However,
chemotherapeutic agents are commonly not specifically targeted to the
rapidly dividing cancer cells, implying that normal cells are also affected,
thus giving rise to significant side effects. Another cancer treatment regime,
still in development, concerns gene therapy, which relies on the reintro-
duction of a functional gene or the silencing of an ill functioning gene that
gives rise to the cancerous state. Yet, irrespective of the chosen therapeutic
strategy, reintroducing a functional gene, silencing a dysfunctional protein
or inducing cell death by applying chemotherapeutic agents, the success
rate of the treatment also very much depends on the ability of the ‘drug’ to
efficiently reach intracellular targets. Thus, both chemotherapy and gene
therapy would greatly benefit from a more accurate (intra) cellular delivery
of the ‘drug’, so as to eliminate side effects of chemotherapy and increase
the efficiency of gene therapy.
To achieve such goals, sophisticated delivery devices or ‘nanoparticles’
are currently developed and applied in order to effectively and specifically
guide the therapeutic agents to their targets. In this manner, potential
therapeutic genes are protected against degradation in the blood while
encapsulated chemotherapeutics can in principle be precluded from en-
tering ‘healthy’ cells. A great variety of nanoparticles are currently eval-
uated for such applications, including so-called Solid Lipid Nanoparticles
(SLNs). These particles are biocompatible, physically stable, easily allow
for large-scale production, and have been shown of being able to deliver
drugs and/or genes into cells. In this thesis we have investigated the po-
tential use of SLNs as a tool to improve intracellular delivery of genes and
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drugs in the treatment of cancer. Specifically, detailed studies are presented
on the interaction of solid lipid nanoparticles with and their processing by
normal prostate and prostate cancer cells in vitro.
In Chapter 1 we address recent advances in the use of Solid Lipid
Nanoparticles as platform for delivery of nucleic acids as therapeutic
agents. In particular, we focus on underlying molecular mechanisms by
which SLNs and nucleic acids assemble into complexes, and how the nu-
cleic acid cargo may be released intracellularly. Thus, we developed a
coherent model of the interaction between SLNs and nucleic acids and
pointed out the key differences between the intracellular release mecha-
nisms of cationic lipid-based liposomes and SLNs as gene delivery devices.
Thus, a concise and critical overview is provided of the knowledge on the
use of SLNs for gene delivery, which appears fairly limited so far, when com-
pared to mechanistic knowledge on the use of other nanocarriers, including
those based on (cationic) polymers and cationic lipids. Accordingly, further
successful development of SLNs as gene delivery vehicles will greatly de-
pend on the improvement of knowledge on structure-function relationships
of SLNplexes and, consequently, the underlying mechanisms of intracellu-
lar processing.
The first experimental challenge of the work presented in this thesis
was the development of a convenient and versatile procedure for the pro-
duction of SLNs on a laboratory scale. In Chapter 2 we demonstrate that
an approach relying on the use of a mini-extruder can be advantageously
employed to produce solid lipid nanoparticles on a laboratory scale. The
described microemulsion extrusion technique is fast, inexpensive, repro-
ducible, free of organic solvents, and suitable for small volumes. In addi-
tion, the procedure provides a most efficient means of screening for new
formulations of lipid-based carriers, including solid lipid nanoparticles and
nanostructured lipid carriers. Additionally, we show that the produced lipid
nanoparticles are stable and versatile, being applicable in both drug and
gene (i.e., nucleic acid) delivery. In fact, the co-delivery of the chemother-
apeutic drug mitoxantrone and a plasmid, containing the PTEN construct,
successfully reduced the viability of PC3 prostate cancer cells and bypassed
the resistance of MCF-7 breast cancer cells to mitoxantrone.
After having established the production of SLNs, using the microemul-
sion extrusion technique, efforts were undertaken to improve the SLN-
mediated delivery of genes into PC3 prostate cancer cells. Guided by the
notion that distinct helper lipids like DOPE may facilitate the formation
of non-bilayer lipid phases, leading to an enhanced destabilization of the
endosomal membrane and, as a consequence, improved cytosolic deliv-
ery of the plasmid and subsequent transfection efficiency, the effect of in-
clusion of DOPE in the SLN formulation was investigated to evaluate this
hypothesis. Unexpectedly, as opposed to DOPE’s ability to strongly pro-
mote transfection, mediated by cationic liposomes, we observed that in-
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clusion of DOPE into the solid lipid nanoparticles has a detrimental effect
on the gene delivery efficiency of SLNs (Chapter 3). We show that DOPE
in SLN formulations composed of stearic acid/DOTAP/Pluronic-F68 com-
promises DNA-binding and leads to inefficient protection of DNA against
DNase degradation. On the other hand, SLNs devoid of DOPE are shown to
efficiently transfect PC3 cancer cells, and maintain their high transfection
efficiency after lyophilization and long-term storage, an important asset
for biomedical applications. These findings show the potency of develop-
ing SLNs for gene delivery purposes. They also indicate differences in the
mechanism of delivery, when compared to the mechanism of delivery me-
diated by cationic lipid systems, reflecting interesting differences between
both carrier systems that warrant further investigations.
Following the above findings, we subsequently investigated potential
cell type dependent differences in transfection efficiency by careful exam-
ination of the interaction of a given SLN formulation with both normal
prostate cells and their cancerous counterpart. In Chapter 4 we demon-
strate that SLNs are efficiently internalized by human prostate cancer PC3
cells, as well as their non-malignant counterparts, i.e., human prostate ep-
ithelial PNT2-C2 cells. However, PC3 cells become efficiently transfected,
whereas PNT2-C2 cells do not. This is in sharp contrast with transfec-
tion mediated by Lipofectamine, that reaches similar efficiencies in both
cell types. We show that although SLN lipoplexes induce autophagosome
formation in both PC3 and PNT2-C2 cells, this phenomenon is connected
with autophagic degradation in PNT2-C2 cells, but not in PC3 cells, which
showed an incomplete autophagic process. Therefore, we suggest that
a low autophagic flux in the PC3 tumor cells compared to that in non-
malignant PNT2-C2 cells broadens the time window for effective endo-
somal escape of cargo, resulting in its selective and effective release into
the tumor cells, but not their healthy counterparts. We submit that this
finding can be exploited for the ‘targeting’ of gene delivery vectors into
cancer cells. Knowledge about the underlying mechanism of transfection
can be exploited to improve transfection efficiency; here we show that this
can be achieved by taking advantage of how the cells process nanopar-
ticles. Therefore a thorough understanding of endocytosis, cell signaling
and intracellular processing in cancer cells, especially upon interaction with
(gene) vectors, will aid in the rational design of gene/drug delivery sys-
tems.
In Chapter 5 we studied the effect of ferruginol, a natural compound
found in Chilean trees (Podocarpaceae), on prostate cancer cells. We found
that this diterpene reduced cell viability and was capable of inducing apop-
tosis in PC3 cells. Interestingly, ferruginol triggered both intrinsic and ex-
trinsic apoptosis pathways in prostate cancer cells. The induction of intrin-
sic pathways was characterized by the high ratio of Bax:Bcl2, high nuclear
AIF levels and caspase 9 activity. Induction of an extrinsic apoptotic path-
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way was confirmed by the high expression of TNFR1 and a high activity of
caspase 8. Accordingly, ferruginol-treated cells increased caspase 3 activ-
ity, a converging point for both pathways. Besides induction of apoptosis,
ferruginol was able to inhibit survival-signaling pathways (e.g. PI3k/AKT
and MEK/ERK pathways) and proliferation. Finally, we demonstrated that
ferruginol reduced cell survival by inhibiting Hsp27, which in turn desta-
bilizes and inhibits STAT3. The observed effectivity of the free drug on the
prostate cancer cells are encouraging in further developing the system in
terms of the application of SLNs to achieve targeted delivery and an effec-
tive anti-tumor therapy.
6.2 Perspectives
With the research presented in this thesis, we have obtained insight into
the options of applying solid lipid nanoparticle as delivery vehicles, includ-
ing knowledge of the mechanism of delivery, their intracellular processing
and the cellular response. We demonstrated that lipid-based nanoparticles,
including SLNs and nanostructured lipid carriers can be conveniently pro-
duced by a mini extruder according to a method that we refer to as ‘the
microemulsion extrusion technique’. It would be of future interest to ex-
amine whether this method could be readily translated into scale up meth-
ods, such as a high pressure homogenization technique. In particular, the
currently developed procedure allows the preparation of SLNs on a small
volume scale (ml’s), which enables a rapid screening for potentially suc-
cessful formulations, prior to a relatively large scale production, which is
commonly an inherent part of existing procedures, as they preclude the use
of small volumes.
Further, it would be important to better define the physicochemical
characteristics of the internal molecular organization (the ‘core’) of the lipid
nanoparticles. Recently, numerous SLN formulations have been evaluated
as gene delivery systems. Several of those formulations contain a cationic
phospholipid (e.g. DOTAP) or helper lipid (e.g. DOPE). However, inclusion
of liquid crystalline lipids (e.g. the transition temperature of DOTAP is -11,9
°C and that of DOPE is -20 °C) into SLNs that primarily consist of a solid
core, seem to declassify these particles as solid, and should rather be con-
sidered as nanostructured lipid carriers (NLCs); particularly since it should
be noted that this simple modification may have an important impact on the
lipid nanoparticle structure, and hence its functioning. NLCs represent the
new generation of lipid-based nanoparticles, which show some advantages
over SLNs, such as the capacity of modulating drug release, an increase in
drug loading capacity and a reduced cargo leakage. Unfortunately, up to
now this discussion has been neglected in the SLN literature. In fact, this
example illustrates that often only poor attention is paid to details of the
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structure of the lipid nanoparticles, which is nevertheless of relevance for a
better understanding of their properties as a delivery system. Furthermore,
it is also most important to shed further light on the underlying mechanisms
of nucleic acid release from the nanoparticles, since such knowledge will
be essential in further improving the delivery properties and hence, the
transfection efficiency.
The cellular uptake of SLNplexes (the complex that arises upon mixing
SLN particles and the gene of interest) via endocytosis depends on their
binding to the cell membrane. Typically, positively charged nanoparticles
have been thought to efficiently bind to the net negatively charged cell
membrane, which consequently results in the internalization of the nano-
material. Yet, SLNplexes are highly negatively charged nanomaterials that
are effectively internalized by prostate cancer cells. Thus, unlike previ-
ous assumptions that only positively charged particles efficiently interact
with the plasma membrane, our data suggest that the interaction between
cells and nanomaterial may not be solely based on electrostatic interac-
tions. Future investigations should provide more insight into alternative
mechanisms of SLN-cell surface interactions and the consequences these
characteristic may have on in vivo applications. After internalization via
the endocytic pathway, the cargo becomes entrapped in endosomes, which
is eventually processed towards lysosomes, where lysosomal enzymes may
proceed with its active degradation. Escape from the endosome is thus
mandatory for a successful intracellular delivery of nucleic acids; however,
the ultimate molecular mechanisms by which SLN-mediated endosomal es-
cape of its cargo (such as nucleic acids) occurs, remains puzzling. Thus,
concerning the mechanism of transfection, studies of intracellular process-
ing and fate of SLNplexes should aim at providing improved insight into the
mechanism of nucleic acid release. Because in sharp contrast to cationic
liposome-mediated transfection, the transfection properties of SLNs do ap-
parently not depend on lipid mixing or nonbilayer structures that poten-
tially may destabilize endosomal membranes, thereby facilitating release.
Important molecular factors that govern the release of cargo from SLNs
therefore remain to be discovered. In this context, SLNplexes are shielded
by DNA, which may hamper lipid exchange between SLN and the endoso-
mal membrane. The inability to adopt hexagonal conformations and the
detrimental effect of the inclusion of a hexagonal phase promoting helper
lipid (e.g. DOPE) show a key idiosyncratic difference between SLN and
cationic lipid-based liposomes. However, these findings trigger additional
questions that need to be addressed, such as: Do SLNs need to be disassem-
bled to allow for payload release? Which forces drive this event? Clearly,
further insight into the structure-function relationship of these particles is
crucial.
Autophagy has emerged as a mechanism related to nanomaterial toxic-
ity. Recently, autophagy was suggested as a new cellular barrier against
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efficient gene delivery, because cationic nonviral gene delivery vectors
promptly induce the formation of tubulovesicular autophagosomes. In
showing that cancer cells are more efficiently transfected by SLNs, when
compared with normal cells, we were able to correlate this difference with
differences in the process of autophagy in normal prostate cells versus can-
cer prostate cells. The incomplete autophagic process in prostate cancer
cells thus seems to offer a ‘natural approach’ for improved delivery of nu-
cleic acids into prostate cancer cells. It would be of particular interest to
determine whether these findings apply to cancer cells in general, and to
identify the underlying molecular causes of this effect. Finally, it would
also be of great value for therapeutic purposes to investigate if this intrigu-
ing difference between normal and cancer cells can be explored for in vivo
delivery of therapeutics, including nucleic acids and drugs.
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